InterventionsHuman trial

Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Preliminary Results from a Phase 1 Study

ADA Scientific Sessions 2025 Abstract

The paper

MACIAS PULIDO A, HOMPESCH M

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Late-breaking 1980-LB

doi.org/10.2337/db25-1980-lb

Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026